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Background. The World Health Organization’s 2020 goals for Chagas disease are (1) interrupting vector-borne intradomiciliary 
transmission and (2) having all infected people under care in endemic countries. Insecticide spraying has proved efficacious for 
reaching the first goal, but active transmission remains in several regions. For the second, treatment has mostly been restricted to 
recently infected patients, who comprise only a small proportion of all infected individuals.
Methods. We extended our previous dynamic transmission model to simulate a domestic Chagas disease transmission cycle 
and examined the effects of both vector control and etiological treatment on achieving the operational criterion proposed by the Pan 
American Health Organization for intradomiciliary, vectorial transmission interruption (ie, <2% seroprevalence in children <5 years 
of age).
Results. Depending on endemicity, an antivectorial intervention that decreases vector density by 90% annually would achieve 
the transmission interruption criterion in 2–3 years (low endemicity) to >30 years (high endemicity). When this strategy is com-
bined with annual etiological treatment in 10% of the infected human population, the seroprevalence criterion would be achieved, 
respectively, in 1 and 11 years.
Conclusions. Combining highly effective vector control with etiological (trypanocidal) treatment in humans would substantially 
reduce time to transmission interruption as well as infection incidence and prevalence. However, the success of vector control may 
depend on prevailing vector species. It will be crucial to improve the coverage of screening programs, the performance of diagnostic 
tests, the proportion of people treated, and the efficacy of trypanocidal drugs. While screening and access can be incremented as part 
of strengthening the health systems response, improving diagnostics performance and drug efficacy will require further research.
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Chagas disease (whose etiological agent is Trypanosoma cruzi) is 
endemic throughout much of Latin America and is responsible 
for substantial excess morbidity and mortality due to cardiac and 
digestive complications [1, 2]. It is estimated that the global costs 
of Chagas disease are US$7.19 billion per year and US$188.80 
billion per lifetime [3]. In the context of Chagas disease, the 2012 
London Declaration and the World Health Organization (WHO) 
roadmap on Neglected Tropical Diseases proposed that by the 
year 2020, total interruption of intradomiciliary transmission in 
Latin America and provision of care to all infected patients should 
be achieved [4]. However, recent data suggest that antivectorial 
programs are not being sustained in all endemic countries or 
regions [5]. Furthermore, treatment coverage is as low as <1% 
of the infected population [6], and access to care remains limited 
in several countries [7]. Based on clinical efficacy (measured as 
the ability to halt or curb clinical progression to heart compli-
cations), etiological treatment is only considered adequate for 
recent infections, such as acute or congenital cases, and infection 
in children [8]. Clinical efficacy is yet to be demonstrated in late-
stage infections and in adults with advanced heart conditions 
[9]. (Etiological treatment is defined as trypanocidal treatment 
administered and monitored upon diagnosis of infection by poly-
merase chain reaction [PCR] and/or conventional methods.) The 
development of real-time PCR has made it possible to measure 
and monitor therapy; thus, the parasitological efficacy (sustained 
trypanocidal activity) of the currently available drugs has been 
recently tested. Two independent clinical trials have demon-
strated parasitological cure in asymptomatic adult carriers with 
an efficacy of 88% [10] and 94% [11].
Historically, vector control has been the main strategy used 
to prevent Chagas disease transmission. Vector control typically 
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relies on campaigns of indoor residual spraying (IRS) which, if 
done appropriately, have a long-lasting effect, even in hyperen-
demic settings with domiciliated vectors. Successful vector con-
trol campaigns have been carried out against the vector species 
Triatoma infestans in much of the South Cone of South America 
[12], and Rhodnius prolixus in Central America [13]. However, 
active intradomiciliary transmission still occurs in many 
endemic regions, particularly in hard-to-reach populations in 
isolated rural communities of Latin America [5].
Given the high (anti-)parasitological activity of trypanocidal 
drugs and the limited success in interrupting vector-borne 
T. cruzi transmission in several endemic regions, it is important 
to understand the role of other Chagas disease control strategies, 
both alone and in combination with vector control, to inform 
policy makers, researchers, and funders on future directions. 
Here, we examine the role of etiological treatment on Chagas 
disease transmission dynamics, and its potential for helping to 
achieve the WHO 2020 goals. Can etiological treatment reduce 
time to transmission interruption? To answer this question, we 
use a mathematical model of Chagas disease transmission based 
on our previous dynamic model [14] to compare time to intra-
domiciliary interruption of T. cruzi transmission in 2 scenarios: 
(1) deploying vector control (IRS) alone and (2) combining vec-
tor control with etiological treatment (measured as the propor-
tion of parasitological cure (PPC) in the infected population.
METHODS
Transmission Dynamics Model
We expanded our deterministic model first presented in [14], 
which includes vector, human, and animal host populations. 
The model divides the vector population into susceptible 
(uninfected), SV , and infectious individuals, IV . The total vec-
tor population size is determined by a logistic equation with a 
carrying capacity KV  that is related to the size of the human 
population considered. The human population is divided into 
4 categories: susceptible (uninfected) individuals, SH ; acutely 
infected individuals, or those who have recently been infected 
with T.  cruzi, IH
a ; asymptomatic individuals in the chronic 
indeterminate phase, IH
i ; and chronically infected individu-
als who exhibit clinical pathology ( IH
c ). Individuals who reach 
parasitological cure after treatment are moved back into the sus-
ceptible population. To track age-specific seroprevalence status 
and clinical outcomes, the human population is age-structured, 
with a fixed birth rate. We assume that a variety of mammal 
species can act as T. cruzi hosts. This nonhuman host popula-
tion (without explicit age-structure) is divided between SR and 
IR . The reservoir population is related to the size of the human 
population, as many of them are synanthropic (eg, peridomestic 
foraging marsupials).
We included an additional “external” force of infection (FoI) 
upon humans, lH , representing all other processes that take place 
outside the intradomiciliary cycle (eg, sylvatic transmission, oral 
transmission). Similarly, we included an external FoI upon sus-
ceptible reservoirs, lR . Model parameters and values (informed 
by the literature) are presented in Supplementary Table A. The 
full dynamical system and the model’s sensitivity analysis are pre-
sented in the Supplementary Methods.
Vector Control
Vector control (IRS) was modeled by reducing vector density 
by a given proportion following an implementation process that 
was governed by 2 parameters: the final decrease in vector dens-
ity and the time to reach such density. Over the implementation 
period, we gradually increased vector mortality and simultane-
ously decreased their carrying capacity. At the end of the imple-
mentation period, the vector density reached a new level under 
“control” conditions. While the duration of the implementation 
period relates to the initial effort allocated to vector control, the 
final reduction in vector density relates to vector control efficacy 
and coverage. The final modeled level of vector control ranged 
between 0 to 100% annual reduction in vector density. Vector con-
trol was gradually implemented to achieve its final and sustained 
level after 4 months (DVC ) in a village with 10 000 habitants.
Etiological Treatment
The key aspect modeled for etiological treatment was the PPC, 
meaning the proportion of the T.  cruzi–infected human pop-
ulation that effectively reached parasite clearance and subse-
quently moved back into the susceptible population. Notice 
that PPC is calculated as the product of (1) the proportion of 
infected individuals who are tested, pT; (2) the proportion of 
those tested with a positive test result (dependent on the diag-
nostic performance of the test(s) used), pP; (3) the proportion of 
those testing positive who are treated with available drugs and 
finish the entire treatment course, pD; and (4) the proportion of 
infected individuals who are cured (parasitological drug effi-
cacy), pE, after undergoing treatment.
Treatment was modeled by setting the duration of implemen-
tation of human treatment, DHT , and the final value of PPC 
1 year after treatment (ie, modeling the composite product of 
pT, pP, pD, and pE). During the implementation period, the PPC 
(modeled through the proportion of infected humans effect-
ively treated, PHT ) is gradually increased to reach its final level, 
1- -exp( )PHT , which is then maintained constant following 
the implementation period. We used a feasible range of PPC 
values based on the current characteristics of pT, pP, pD, and pE, 
ranging between 0 and 38% of infected humans each year. We 
assumed that the implementation of a treatment program in a 
community of this size would last for 12 months each year based 
on previous experiences of screening and etiological treatment 
programs in endemic areas [15, 16].
The details of the model with antivectorial and antiparasitic 
interventions are provided in the Supplementary Methods, with 
parameters and values listed in Supplementary Table B.
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Scenarios Under Evaluation
We evaluated the impact of vector control (IRS) alone, and in 
combination with etiological treatment, for epidemiological sce-
narios ranging from low to high endemicity (modeled by chan-
ging the vector carrying capacity, see Supplementary Table C). 
To facilitate ease of interpretation, we used values representing a 
low, medium, and high efficacy for vector control and etiological 
treatment impact. For vector control, the low, medium, and high 
efficacy values are presented as reductions in vector density by 
10%, 50%, and 90%, respectively. For etiological treatment, we 
focus on the impact of PPC in 1% (status quo), 10% and/or 20% 
of the total infected population. Age structure is included so that 
results generate age-prevalence profiles, which are indicative of 
the long-term effect of control strategies against Chagas disease 
in human populations.
Transmission Interruption Thresholds
The operational criteria proposed by the Pan American Health 
Organization (PAHO) to certify interruption of intradomicili-
ary vectorial transmission in endemic regions include T. cruzi 
seroprevalence <2% in children aged <5 years [17], absence of 
acute cases in the last 3 years, and other indicators of domes-
tic and peridomestic triatomine infestation. All these criteria 
are currently under review by PAHO. Therefore, we have used 
the serological criterion thus far published [17] as a measure of 
transmission interruption.
RESULTS
Effect of Vector Control Alone and in Combination With Etiological 
Treatment on Seroprevalence in Children Aged <5 Years
Our model predicts that in a moderate endemicity setting, an 
annual 60% reduction in vector density by itself would require 
>45 years to reach the serological criterion for transmission inter-
ruption. By contrast, when implementing etiological treatment of 
infected individuals in combination with vector control, the time 
to achieve the seroprevalence threshold in children would be con-
siderably reduced (Figure 1). For instance, in a moderate endemic 
setting, when PPC is implemented in combination with vector con-
trol, and increased to 20%, the time to reach <2% seroprevalence in 
children decreases from 45 to 5–6 years, a decrease by 80%–90%.
Effect of Vector Control Alone and in Combination With Etiological 
Treatment on Overall Infection Prevalence in the Human, Reservoir, and 
Vector Populations
Vector control alone must be implemented very intensively and 
over prolonged periods (eg, decades) to reduce markedly T. cruzi 
Figure 1. Combined impact of vector control and effective parasite clearance (measured as proportion of parasitological cure [PPC]) on years to reduce seroprevalence in 
children under 5 to <2%. Annual vector control defines the proportion by which vector density is reduced (0–100%); annual PPC defines the proportion of humans effectively 
treated, ie, the percentage of the infected human population achieving parasitological cure (0–40%). The color scale corresponds to number of years to achieve the serolog-
ical criterion. The panels represent: A: low; B: moderate; C: high; D: very high endemicity levels (see Supplementary Materials).
Downloaded from https://academic.oup.com/cid/article-abstract/66/suppl_4/S293/5020636
by Imperial College London Library user
on 25 June 2018
S296 • CID 2018:66 (Suppl 4) • Cucunubá et al
prevalence. In a highly endemic setting, an annual 90% reduction in 
vector density would take 30 years to reduce overall human infec-
tion prevalence to 5% and domiciliated triatomine infection prev-
alence to 70%. Contrastingly, adding etiological treatment, even 
at the relatively low level of 10% PPC, would lead to much faster 
reductions in infection prevalence, reaching, after 30 years, 7% in 
the human population (<60% in the reservoir population) even for 
moderate reductions (50%) in vector density. Higher reductions in 
vector density (90%), in combination with 10% PPC, would result 
in human and reservoir infection prevalence levels well below 1% 
and 15%, respectively, and <40% in the vector population (Figure 2).
Effect of Vector Control Alone and in Combination With Etiological 
Treatment on Age-Specific Prevalence in the Human Population
The model predicts that, in a highly endemic setting, if deployed 
on its own, only an aggressive (90% reduction in vector density) 
and prolonged (>10 years) vector control strategy would reduce 
prevalence in children under 5 to <2%. It would take >15 years 
to reduce prevalence to <5% in children aged 5–15  years. If 
vector control strategies are implemented in combination 
with etiological treatment that achieves 10% PPC in the total 
infected human population per year, the time to achieve the for-
mer of these serological thresholds would be reduced by half, 
also leading to marked declines in T. cruzi infection prevalence 
in all age groups (Figure 3).
The role of etiological treatment on the T.  cruzi infection 
dynamics in humans depends on increasing 4 potential com-
ponents of effective treatment: (1) the proportion of human 
hosts tested for T. cruzi infection; (2) the proportion diagnosed 
as positive for T. cruzi infection according to the test(s); (3) the 
proportion of these being treated for T. cruzi with a trypano-
cidal drug; and (4) the proportion who respond to treatment 
by completely clearing T.  cruzi. The net effectiveness at the 
population level, or PPC, is the product of all 4 components 
and thus effective levels can be achieved by increasing some 
or all of the components of the effective parasite clearance. 
Figure 4 illustrates some possible combinations (of diagnostic 
and treatment probabilities) that would lead to achieving 10% 
or 20%  PPC,  given  a  range  of  proportions  of  infecteds  (20–
90%) covered by a test and treat program.
DISCUSSION
We have expanded a previous mathematical model of T. cruzi infec-
tion to explore the impact of etiological treatment combined with 
vector control on shortening timeframes for achieving interruption 
Figure 2. Infection prevalence in humans (red lines), nonhuman mammal hosts (green lines), and domiciliated Trypanosoma cruzi vectors (blue lines) over 30 years following 
the implementation of sustained and continuous control strategies beginning at year 1. A, B, and C present, respectively, prevalence trends following vector control on its own 
that leads to 10%, 50%, and 90% reductions in vector density. D–F depict prevalence trends following implementation of vector control (same reductions in vector density as 
above) in combination with an annual 10% proportion of parasitological cure in the population through treatment of the T. cruzi–infected human population.
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Figure 3. Age-specific prevalence profiles of Trypanosoma cruzi infection in the human population in a highly endemic setting, following over 30 years the implementa-
tion of sustained control strategies. A, B, and C present, respectively, age prevalence profiles corresponding to vector control and status quo treatment (1%), with annual 
reductions in vector density of 10%, 50%, and 90%. D–F depict human T. cruzi infection prevalence profiles following the same reductions in vector density as above in 
combination with etiological treatment that effects a 10% population parasite cure among the infected population annually. Horizontal blue dashed lines indicate the 2% 
seroprevalence threshold in children under 5. The color scale represents time, with blue representing the beginning of the intervention and red representing 30 years of 
sustained intervention.
Figure 4. Probability of achieving 10% proportion of parasite clearance (PPC; A) or 20% PPC (B) in a T. cruzi–infected human population based on the combined probability 
of being diagnosed and treated for Chagas disase. The horizontal axis represents the combined contribution of diagnosis as a product of the proportion of infected people 
who are tested (pT) and the proportion of those tested with a positive test result, that is, the sensitivity of the test (pP). The vertical axis represents the combined contribution 
of treatment, as the product of the proportion of those testing positive who are treated with currently available drugs (pD) and respond to treatment by clearing parasites 
according to efficacy (pE). Colored lines represent the proportion (p) of infected people who would have to be reached by a test and treat program (90% [blue], 50% [red], 33% 
[green], and 20% [orange]) to achieve the desired level of effective PPC.
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of intradomiciliary transmission of Chagas disease. Our model out-
puts suggest that the combination of antivectorial and antiparasitic 
measures would considerably decrease the incidence (measured 
as seroprevalence in children under 5) and overall prevalence of 
Chagas disease in the human population compared to antivectorial 
measures alone. Time to achieving the currently published serolog-
ical criterion for intradomiciliary transmission interruption would 
be halved (when 90% of vector density is reduced and 20% PPC is 
sustained, Figure 1), and the benefit would extend to all hosts in the 
transmission system (vectors, humans and reservoirs) even when 
PPC is as low as 10% (Figure 2). This increase in effectiveness is 
achieved because treatment of infected humans reduces the num-
ber of humans infecting susceptible vectors, which, in combination 
with reductions in intradomiciliary vector density, would reduce 
the rate at which newly infected human cases arise.
It must be emphasized, however, that the modeled reductions 
in intradomiciliary vector density assume that IRS will be effect-
ive for triatomine vector control in all endemic areas, includ-
ing the southern parts of North America (Mexico), Central 
America, and northern parts of South America (eg, Colombia, 
Ecuador, northern Peru), where transmission is still ongoing. 
This assumption is based on the previously documented success, 
in the Southern Cone of South America, in curtailing transmis-
sion by T. infestans. However, it is important to note that tria-
tomine populations across the continent are heterogeneous in 
terms of species composition and likely also in their susceptibil-
ity to the insecticides used in IRS. The major triatomine vector 
of Chagas disease in Central America, Ecuador, and other areas 
of northern South America is Triatoma dimidiata. This species 
can be found in sylvatic, peridomestic, and domestic habitats. 
Nondomiciliated populations may act as sources of reinfesta-
tion and become involved in transmission to humans [18]; the 
vector control approaches based on IRS that have been used for 
T. infestans may not work equally well for T. dimidiata.
Our results highlight that treatment of patients with Chagas 
disease does not need to be 100% effective to reduce transmis-
sion to levels that meet the 2020 criteria; the impact of drugs with 
<100% efficacy can be compensated for if enough patients are 
diagnosed and treated. Unfortunately, there is a number of con-
straints in the treatment of T.  cruzi–infected humans: (1) most 
asymptomatic patients do not know they are infected and do not 
seek treatment until they are in the chronic (determinate) phase 
of infection [1]; (2) drugs currently available work best in younger 
and more recently infected acute patients [19]; and (3) severe drug 
adverse events reduce the number of persons completing (adher-
ing to) treatment [9]. This, and the prospects that we may not yet 
have a protective vaccine against Chagas in the near future despite 
efforts toward this [20, 21], highlight the need for better access to 
diagnosis and treatment as well as for new drugs to be developed 
that have fewer side effects and lead to improved compliance.
Achieving a high proportion of PPC in the population is chal-
lenging in many respects, although our results indicate that even 
moderate levels of etiological treatment can go a long way if com-
bined with highly effective vector control (but see the caveats high-
lighted above). Based on current estimates of access to screening 
and etiological treatment, at <1% of infecteds [6], a diagnostic 
sensitivity estimated for available serological tests at 90%, a rate 
of abandonment of treatment at 20–30% [9], and a trypanocidal 
efficacy at 90% [10, 11], it would have been unrealistic to model 
strategies in which the effective parasite clearance in the population 
would have been high (thus our PPC values ranged from 0 to 38%). 
In fact, reaching a 40% PPC would require a proportion of screen-
ing as high as 70%. Of all the components of PPC, the major public 
health challenge will be increasing access to screening, currently 
the weakest link in the equation. Therefore, finding alternative and 
less costly screening strategies is paramount. Some studies have 
evaluated strategies of targeted screening in clusters of individuals 
who are at the highest risk of infection [22].
Promising progress toward the development of better diag-
nostics has been reported in recent years, with validation of rapid 
diagnostic tests (RDTs) showing similar performance to classical 
serological tests. RDTs have the additional benefit of requiring 
less trained personnel and laboratory infrastructure [23]. Table 1 
summarizes potential strategies for improving the PPC.
Table 1. Potential Strategies for Improving the Proportion of Parasitological Cure in a Population of Trypanosoma cruzi–Infected Humans
Strategy Current Situation Potential for Improvement
Screening <1% of populations in areas at risk of vecto-
rial transmission are tested [6]. (In purposely 
designed screening programs, coverage has 
reached 70% [15])
Design screening campaigns and PoC diagnostics that reach the largest 
proportion of Trypanosoma cruzi–infected individuals (in addition to chil-
dren); introduce screening tests in antenatal clinics and routine hospital 
visits in endemic areas or target populations
Diagnostic test performance Sensitivity of serological diagnostics varies be-
tween 90% and 95% [24]
Increase sensitivity and specificity of diagnostics, especially for measuring 
parasitological cure
Access to and abandonment of 
etiological treatment
Low access to treatment among T. cruzi–infected 
individuals and high rate of abandonment be-
cause of SAEs [9, 25]
- Reduce barriers to access to treatment
- Improve availability of drugs
- Reduce SAEs
- Increase supervision by medical professionals during treatment course
Parasitological efficacy (sus-
tained parasite clearance)
Reported at 88% and 94% in 2 clinical trials, meas-
ured by real-time PCR [10, 11]
Develop novel drugs
Abbreviations: PCR, polymerase chain reaction; PoC, point of care; SAE, severe adverse event.
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Paradoxically, although antitrypanosomal drugs can be more 
efficacious in children, this is the population group with the 
lowest prevalence, particularly in regions with long-term vector 
control programs in place. A further development of our model 
will be to evaluate different strategies for reaching the highest 
possible proportion of infected humans, with potential benefits 
for both transmission and disease burden impact. Other poten-
tial strategies to be evaluated could include increasing the age 
range at which diagnosis and treatment are implemented.
The current seroprevalence threshold of <2% in children 
aged <5 years is presently under evaluation by PAHO with the 
aim of extending the age class to which the criterion should be 
applied and/or lowering the seroprevalence level. A  broader 
age class will make it even more critical to consider interven-
tions that complement vector control, which is supported by 
our results. The serological criterion as an operational thresh-
old for transmission interruption should be accompanied by 
vector indicators of decreased presence of domiciliated vectors 
[17], another potential avenue for further investigation with 
our model. Besides, PAHO has not yet determined targets for 
the proportion of T. cruzi–infected individuals under care. To 
this end, our model could help to inform the potential PPC that 
would need to be achieved and the impact of etiological treat-
ment on transmission and disease burden goals.
There are limitations to this study. The failure to interrupt 
intradomiciliary vectorial T. cruzi transmission in the Americas 
is likely to be linked not only to a lack of systematic implemen-
tation of vector control—particularly in hard-to-reach popula-
tions such as rural and indigenous communities [5]—but also 
to the existence of other T.  cruzi transmission cycles, such as 
the presence of sylvatic vector populations in close contact 
with humans, against which IRS is not as efficacious as with 
domestic transmission [26]. Vector control has been very effi-
cacious in areas with exclusively domiciliated vectors, as is the 
case of Central American countries [13]. Regions where vector 
domiciliation has occurred as a result of close proximity with 
sylvatic cycles represent a major obstacle for vector control 
interventions. In our model we represented the role of the syl-
vatic transmission cycle by adding an external FoI on humans 
and reservoirs that represents processes taking place outside the 
domestic cycle. This allows the system always to retain the pos-
sibility of T. cruzi transmission. Although this can be seen as a 
simplistic representation of these processes, we have parame-
terized this using FoI estimates originating from environments 
where the sylvatic cycle predominates and domiciliated vectors 
are absent [5, 27]. We acknowledge that this external FoI can 
be heterogeneous in different environments; further modeling 
is needed to reflect spatiotemporal changes in this parameter, 
including diversity of vector species as indicated above [18].
Although we focused on the potential impact on an already 
well-documented trypanocidal efficacy, we acknowledge that 
the clinical efficacy of etiological treatment in T. cruzi–infected 
adult populations—essential for reducing Chagas disease bur-
den—has not been proven [9]. In fact, there is a perception 
that current intervention (antivectorial and antiparasitic) 
tools against T.  cruzi are insufficient to eliminate Chagas dis-
ease in areas where transmission is currently highest in Central 
America and northern parts of South America [18].
In conclusion, our model suggests that control programs 
would benefit from combining vector control with etiological 
treatment of infected individuals. In terms of vector control, 
however, its effectiveness will depend on the regional and local 
vector species involved in or contributing to intradomiciliary 
transmission and their intrinsic susceptibility to IRS interven-
tions. In terms of etiological treatment, model outputs illustrate 
that even moderate proportions of annual PPC (10%–20%) 
would reduce time frameworks for achieving serological 
thresholds indicative of transmission interruption, infection 
prevalence in vectors, humans, and reservoirs, and ultimately 
Chagas disease burden.
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